Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post-translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments. The epigenome of HCC remains understudied. To better understand the epigenetic underpinnings of HCC, we performed a genome-wide assessment of 5mC, 5hmC, four histone modifications linked to promoter/enhancer function (H3K4me1, H3K27ac, H3K4me3, and H3K27me3), and transcription across normal, cirrhotic, and HCC liver tissue. Implementation of bioinformatic strategies integrated these epigenetic marks with each other and with transcription to provide a comprehensive epigenetic profile of how and when the liver epigenome is perturbed during progression to HCC. Our data demonstrate significant deregulation of epigenetic regulators combined with disruptions in the epigenome hallmarked by profound loss of 5hmC, locus-specific gains in 5mC and 5hmC, and markedly altered histone modification profiles, particularly remodeling of enhancers. Data integration demonstrates that these marks collaborate to influence transcription (e.g., hyper-5hmC in HCC-gained active enhancers is linked to elevated expression) of genes regulating HCC proliferation. Two such putative epigenetic driver loci identified through our integrative approach, COMT and FMO3, increase apoptosis and decrease cell viability in liver-derived cancer cell lines when ectopically re-expressed. Conclusion: Altogether, integration of multiple epigenetic parameters is a powerful tool for identifying epigenetically regulated drivers of HCC and elucidating how epigenome deregulation contributes to liver disease and HCC. (Hepatology 2019;69:639-652).
H epatocellular carcinoma (HCC), the most prevalent primary tumor of the liver, is projected to become the third leading cause of cancer mortality worldwide by 2020.
(1) HCC almost always occurs in the background of liver cirrhosis. Cirrhosis and HCC are driven by several etiologic "environmental" exposures including chronic alcohol abuse, hepatitis B and hepatitis C viral infection, and, increasingly, metabolic disorders from highfat Western diets. (2) Direct-acting antivirals are effective in eradicating hepatitis C virus (HCV), although hurdles to their widespread use remain, due to surveillance, cost, and residual disease following treatment. In addition, elimination of HCV infection or alcohol abuse does not completely eliminate risk for HCC in patients that have developed cirrhosis. (3) Despite intensive research, the 5-year survival rate for HCC has remained unchanged at <12% because of a lack of early detection strategies and effective therapies. (4) Thus, it is crucial to gain a more complete understanding of the pathological processes driving cirrhosis and HCC.
Although it is likely that etiologic risk exposures drive HCC through both genetic and epigenetic mechanisms, epigenetic modifications appear to be profoundly disrupted preceding detectable malignancy. (5, 6) Epigenetic marks on the DNA, including 5-methylcytosine (5mC, mediated by the DNA methyltransferases [DNMT] DNMT1, DNMT3A, and DNMT3B) and 5-hydroxymethylcytosine (5hmC, mediated by the ten-eleven translocation [TET] family TET1, TET2, and TET3), are critical regulators of development that frequently become deregulated in and directly contribute to tumorigenesis. (7) 5mC and 5hmC influence transcription through their differential enrichment at regulatory elements like promoters and enhancers. (8, 9) These patterns are markedly deregulated during transformation as manifested by global loses in 5mC accompanied by region-specific gains. (7) 5mC and 5hmC interface with epigenetic post-translational modifications of the core histones, including methylation and acetylation, to establish proper growth control. Little is known about how deregulated histone modifications influence liver disease. Recent studies show that elevated expression of histone modifiers such as enhancer of zeste homolog 2 (EZH2; writer for the H3K27me3 repressive mark) correlate with HCC stage and survival. (10) Thus, alterations in histone marks may be equally widespread and contribute to HCC, necessitating that an integrative approach be taken to elucidate the role of epigenetic deregulation in driving HCC.
In the current study, we took such an integrative approach by deeply profiling a panel of DNA and histone marks that are key regulators of transcription, in a clinically well-annotated panel of human normal, cirrhotic, and HCC liver tissues, to determine how the epigenome evolves during disease progression and identify driver events linked to epigenetic deregulation. Our results reveal distinctive alterations in all investigated epigenetic marks in cirrhotic and HCC liver tissue, with many such changes linked to transcriptome signatures specific to disease stage. Analysis of histone modifications reveals stage-specific gains in enhancers that correlate with elevated expression of disease-relevant pathways. A marked genome-wide loss of 5hmC occurs during cirrhosis, a phenomenon that is largely maintained in HCC, indicating that 5hmC deregulation precedes transformation. Interestingly, a modest number of 5hmC gain events are observed and are linked to gained enhancers and elevated gene expression. In contrast to 5hmC, de novo 5mC events are extensive and frequently correlate with gene repression. 
Materials and Methods

dNa MetHylatIoN/ HydRoXyMetHylatIoN
Reduced representation bisulfite sequencing (RRBS) was performed as described. (11) Libraries were
prepared following a standard RRBS protocol from size-selected MspI digested genomic DNA isolated from liver tissues. Sequencing on an Illumina HiSeq 2500 was performed at the Medical Genome Facility at Mayo Clinic Rochester followed by QC, processing, and alignment through the streamlined analysis and annotation pipeline for reduced representation bisulfite sequencing (Supporting Table S1 ( 12) ). All sequencing-based data has been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE112221. Additional information can be found in the Supporting Material. Methylated DNA immunoprecipitation-real-time quantitative PCR was performed as described previously. (11) geNe eXpReSSIoN RNA-seq was performed as previously described. (11) Gene expression is represented as fragments per kilobase of transcript per million mapped reads. All realtime quantitative RT-PCR analyses were performed in triplicate, as in Tiedemann et al. (13) Primers are listed in Supporting Table S2 and in Tiedemann et al. (14) Additional detail is provided in the Supporting Material.
HIStoNe ModIFICatIoNS
Chromatin immunoprecipitation (ChIP-seq) was performed as previously described. (11, 14) Briefly, samples were fixed with 1% paraformaldehyde and digested with micrococcal nuclease to isolate nucleosomes. Sonication was performed using a Diagenode Bioruptor. Chromatin input was measured using a Qubit Fluorometer (Thermo Fisher). The following antibodies were used: H3K4me1 (ab8896; Abcam), H3K27ac (ab4729; Abcam), H3K4me3 (ab8580; Abcam), and H3K27me3 (#9733; CST). Samples were 51bp paired-end sequenced on the Illumina HiSeq 2500. Peaks were called using SICER. (15) 
FUNCtIoNal aSSayS
Three liver cell lines (Hu1545, Hep3B, and Huh7) were used to investigate the effect of ectopic re-expression of putative epigenetic driver genes on cell growth. Hu1545 is a human telomerase reverse transcriptase-immortalized normal hepatocyte, which serves as a "normal" reference. Hep3B and Huh7 are HCC-derived. Cell viability is assessed using PrestoBlue Cell Viability Reagent (A13261; Thermo Fisher) according to the manufacturer's specifications, using a BMG FLUOstar Omega plate reader. Colorimetric measurement of caspase 3 (CASP3C; Sigma-Aldrich) is used as a surrogate for activation of the apoptosis pathway using standard protocols. Cell invasion assays (Cytoselect; Cell Biolabs, Inc) were performed according to manufacturer's instructions. All assays are performed in triplicate. Additional information is contained in the Supporting Material.
SoFtWaRe paCKageS aNd StatIStICal aNalySIS
Ingenuity Pathway Analysis (IPA; Qiagen) is used for gene ontology and comparative analyses. Basic summarization, visualization, and statistical analysis are performed in R. Phyloepigenetic trees are constructed using the R package "ape." Chromatin Hidden Markov modeling (ChromHMM) is used to construct histone modification state models. (16) Browser views were obtained from the University of California Santa Cruz Genome Browser. Additional description is provided in the Supporting Material.
Results
deFININg tHe NoRMal lIVeR epIgeNoMe
To elucidate the role of the epigenome in driving liver disease and HCC, 10 fresh-frozen patient liver samples were macrodissected and deeply profiled for epigenetic marks and expression, including two normal tissues (no cirrhosis or HCC, NL-1/ NL-2) and four matched cirrhosis-HCC pairs (Cirr1-4/HCC1-4) (Supporting Tables S1 andS3) . A series of genome-wide methods was performed on each of the samples, including the following: RRBS for 5mC and a TET-assisted modification of RRBS (termed here TAB-RRBS (17) ) for 5hmC; ChIP-seq for four histone modifications including H3K4me1 (poised enhancers), H3K4me3 (promoters), H3K27ac (active enhancers when co-localized with H3K4me1, and active promoters when colocalized with H3K4me3), and H3K27me3 (polycomb repressed regions or bivalent loci when co-localized with H3K4me3); and RNA-seq for gene expression. A global summary of these data is shown as a Circos plot (Supporting Fig. S1A (18) ) and in numerical form in Table 1 .
We first compared the data derived from our normal liver samples against each other and with publicly available data to validate our methods, and to establish a reliable normal liver reference epigenome/transcriptome to permit accurate quantification of diseaserelated changes. Datasets from normal tissues were obtained from ENCODE (Liver, E066; Brain, E071; Small intestine, E109; and Lung, E096). Based on gene expression, our normal liver samples are highly similar to one another (R = 0.98), but substantially different from other tissues, as expected (Supporting Fig. S1B ). Similarly, more than 80% of enhancer-associated H3K4me1 and H3K27ac peaks from our normal liver samples reciprocally overlap with ChIP-seq derived from ENCODE normal liver (Supporting Fig.  S1C ), consistent with previous reports demonstrating that enhancers are tissue specific. (19) Furthermore, 5mC and 5hmC show a high degree of correlation in normal liver (R = 0.93 and 0.83, respectively) between samples in the RRBS/TAB-RRBS data (Supporting Fig. S1D ,E), thus establishing a normal liver reference epigenome (Supporting Fig. S1F shows a representative region). We also compared results derived from different genome-wide 5mC/5hmC measurement platforms from our normal liver tissues, including the Illumina Infinium MethylationEPIC (850k) and 450k BeadChip arrays (Supporting Fig. S2A,B) , which revealed good concordance. Examination of individual loci with significant overlap between Infinium 850k and RRBS data within four genes (lecithin-cholesterol acyltransferase [LCAT] , C1ORF159, PVRL4, and TNR) demonstrates a high degree of conservation between deep sequencing and array-based measurements for both methylation and hydroxymethylation (Supporting Fig. S2C-F) .
geNe eXpReSSIoN
We next assessed gene expression profiles in our normal, cirrhotic, and HCC liver samples using RNA-seq (Table 1; Supporting Tables S1 and S3 Differentially expressed loci involved in pathways related to immune function (e.g., lymphocyte migration) are preferentially enriched in cirrhotic tissue, whereas HCCspecific gene expression changes are more strongly associated with terms including "invasion of tumor" based on IPA (Fig. 1D ). However, several upstream regulators are enriched in both disease stages; many of these are associated with general hepatic function and are intimately linked to liver disease (e.g., WNT1, TGFB1; Supporting Fig. S3D ). Interestingly, many inflammation-related genes upregulated in cirrhosis are associated with survival differences in patients with HCC (Supporting Table S4 ).
Given the epigenetic marks we are examining, and the moderate frequency of chromatin regulator mutations in HCC, (20) we performed a focused expression analysis on a set of relevant epigenetic writers, readers, and erasers. Many of these genes demonstrate changes in expression, including a stepwise loss of TET2 ( Fig. 1E ; P = 0.07) representing Cirrhosis  63941  5253  7130  135582  1126  136  27425  11849  27006  13653  26515  60566  55413  68679  HCC  90148  26096  4554  169342  1723  357  35492  26393  24107  31561  33303  57898  51497  65264 at least one potential contributor to deregulation of the 5hmC mark in liver disease (as described later). DNMTs are upregulated in both cirrhosis and HCC, consistent with previous reports. (21) The H3K27me3 writer EZH2 is stepwise upregulated in cirrhosis and HCC and significantly associated with poor survival (Fig. 1E (10) ). Frequently mutated regulators of chromatin in HCC (≥6%), including ARID1A, ARID2, SETD2, and RB1, show minimal changes in expression. Examination of expression in the same panel of epigenetic regulators (Fig. 1E) in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA LIHC) data set reveals several striking correlations. For example, EZH2, which is upregulated in our RNA-seq data set in HCC, is also upregulated in 98% of HCCs in the TCGA data set (367/373 HCCs). Similarly, TET2, which is downregulated in our data set, is downregulated in 73% of HCCs from TCGA. DNMT1, DNMT3A, and DNMT3B are upregulated in our data set, consistent with upregulation in 88%, 91%, and 91% of TCGA HCC samples, respectively. Of the genes covered in our study and TCGA, 1,469 (91%) of our 1,606 upregulated genes show concordant expression changes in the TCGA data set (Fig.  1F) . Similarly, 155 (67%) of the 231 downregulated genes are consistent between the two data sets. This analysis further confirms that our results, derived from a smaller sample set, reflect liver disease and that differences we identify are likely broadly applicable to HCC biology.
HIStoNe ModIFICatIoNS
To address the gap in knowledge regarding the dynamics of histone modifications in liver disease, we performed ChIP-seq for four histone marks key to the control and definition of promoters and enhancers in a single normal liver tissue and two cirrhosis-HCC pairs previously analyzed by RNA-seq ( Fig. 2A ; Table 1; Supporting Tables S1 and S3 ). By assessing combinations of marks, we can define regulatory element classes most affected across disease stages. Bivalent loci (marked by H3K4me3 and H3K27me3, generally lowly expressed but poised for activation or repression (22) ), for example, are relatively unique to each disease stage (Fig. 2B, left) . In contrast, active enhancers (marked by H3K4me1 and H3K27ac) are much more highly conserved across the three stages (Fig. 2B, right) .
To elucidate how histone modifications evolve during hepatocarcinogenesis, we performed ChromHMM (16) using our four histone marks (Fig.  2C) . Each combination of histone marks is linked to regulatory elements and/or genome features, derived from a prior study. (23) ChromHMM reveals a number of interesting findings; for example, new active enhancers (state 7; presence of H3K4me1 and H3K27ac) are enriched in cirrhotic tissue. To examine the dynamics between two stages of disease, we plotted the 10 states in normal liver and determined their corresponding states in cirrhosis and HCC ( Fig. 2D; Supporting Fig. S4A-C) . As each state in normal liver may remain unchanged in disease or transition to a different state, we can understand the dynamics of histone modifications genome-wide by simplifying them into 10 possible configurations (i.e., states). For example, genes associated with quiescent regions (unmarked, state 1 in Fig. 2C ) in normal liver generally remain quiescent in tumor (89% of the total regions in this category; Fig. 2D ; first bar; Supporting Fig. S4B ; first bar). However, 5.6% of genes that were formerly quiescent ( Fig. 2D ; first bar) gain enhancer marks in liver disease (state 7, H3K4me1 and H3K27ac; and state 8, H3K4me1 for poised enhancers). Many bivalent loci (state 3, third bar; H3K4me3 and H3K27me3 together) become epigenetically silenced (14.6%) following loss of H3K4me3. State 2 frequently loses repressive H3K27me3 to become unmarked (59%), whereas the H3K27ac-associated state 6 frequently acquires H3K4me1 to become an active enhancer (41%, state 7). Thus, although much of the epigenome remains unchanged in cirrhosis and HCC, many specific regions display marked epigenetic switching, particularly those linked to enhancers.
Within individual cirrhosis-tumor pairs (e.g., Supporting Fig. S4A,B) , enhancers are major targets for epigenome remodeling. For example, regions with H3K4me1 or H3K27ac alone (sixth and eighth bars) become active enhancers at high frequency in cirrhosis and HCC. To test whether these state transitions impact transcription, we examined matched RNA-seq data for each sample to determine whether specific state transitions impact expression. Indeed, cirrhosis-associated gain of active enhancer marks in normally quiescent loci is associated with increased transcription (Fig. 2E) and is linked to "hematologic system development and function" using IPA. In addition, when repressive H3K27me3 is removed from a bivalent promoter to transition to an active promoter, we observe increases in transcription of loci associated with "generation of tumor" (Fig. 2F) . Finally, gain of the activating mark combination H4K4me3 and H3K27ac (state 5), is enriched in liver disease and is linked to upregulation of genes associated with these regions (Fig. 2C,D; Supporting Fig. S4A-D) . Taken together, this analysis demonstrates that histone modifications are significantly altered in cirrhosis and HCC, with particular enrichment for changes in enhancers leading to widespread gene upregulation.
dNa MetHylatIoN/ HydRoXyMetHylatIoN
We next performed RRBS to assess DNA methylation across the genome. Given that standard RRBS measures the summation of 5mC and 5hmC, and because 5hmC is emerging as a mark particularly sensitive to environmental perturbations, (24) we also performed TAB-RRBS (17) to specifically interrogate 5hmC. We observe genome-wide increases in 5mC in both cirrhosis and HCC (Fig. 3A,B upper panels) . However, 5hmC is markedly depleted in cirrhotic tissues, and remains low in HCC, with only a small fraction of CpG sites gaining hydroxymethylation (~0.5% of CpGs linked to genes; Fig. 3A ,B lower panels). Comparing the dynamics between cirrhosis and HCC, we observe that in cirrhosis 5mC is gained preferentially at regions that already possess moderate to high levels of 5mC in normal liver. However, HCC also displays a clear increase in de novo hypermethylation events (Fig. 3A, top panels) . Gains in 5mC are prominent at transcription start sites (TSS), with a stepwise increase from normal to cirrhosis to HCC (Fig. 3B, top panel) . 5hmC loss is a genomewide effect, with little evidence for changes specifically focused on the TSS, as these regions are already depleted for 5hmC in normal liver (Fig. 3B, bottom panel). The loss of 5hmC is further supported by mass spectrometry (liquid chromatography-tandem mass spectrometry) analysis of genomic DNA (Supporting Fig. S5A,B ). Mass spectrometry quantification shows a modest overall reduction in total 5mC levels, whereas RRBS shows an increase in average methylation. This is likely due to 5mC loss in intergenic and repetitive regions in mass spectrometry measurements, as has been observed in many cancers, (7, 25) whereas RRBS has an inherent bias towards CG-rich regions including promoters. (26) We recently reported that DNA methylation displays substantial heterogeneity within individual patient liver tissues that correlates with cell proliferation. (5, 27) A subset of cirrhotic regions is epigenetically more "aggressive," which correlates highly with an "epigenetic progression" score derived from phyloepigenetic tree reconstruction.
(5) Applying a similar concept to samples in this study, we observe that 5mC robustly segregates normal, cirrhosis, and HCC (P = 0.05; cirrhosis vs. HCC; Fig. 3C, left) , whereas 5hmC shows no such separation, but both disease states segregate from normal liver based on 5hmC (P = 0.89; cirrhosis vs. HCC; Fig. 3C, right) . To address whether the DNA mark changes we observe represent "switching" between 5mC and 5hmC during disease progression, we plotted changes in each mark against one another in promoter regions (Fig. 3D) . Because there are relatively few hyperhydroxymethylation events, it is not surprising that relatively few CpGs (~0.3%) gain 5hmC with or without changes in 5mC (within 200 bp upstream of the TSS; TSS200) in cirrhosis and HCC relative to normal liver (Fig. 3D,  upper right quadrants) . However, a significant number of promoter-associated CpGs gain 5mC at the expense of 5hmC (~3,000 sites in cirrhosis and ~3,500 in HCC; Fig. 3D, upper left quadrants) . We performed IPA on genes that switched from 5hmC to 5mC in the TSS200 region in HCC and identified pathways associated with liver tumorigenesis as among the most enriched (Supporting Fig. S5C ). As a specific example, we selected a gene from the 5hmC to 5mC switching TSS200 ontology, LCAT, to examine whether switching correlates with expression at loci identified in Fig.  3D . As Fig. 3E shows, 5mC progressively increases at the LCAT promoter during disease progression with a corresponding decrease in expression (R 2 = 0.55; Supporting Fig. S5D,E) . Querying the much larger TCGA HCC sample set reveals that lower LCAT expression correlates with poorer survival (Fig. 3F,  left) . LCAT 5mC data from the TSS200 region is also significantly associated with survival (Fig. 3F, right) . Further examination of LCAT reveals that it is among the top 10 most differentially expressed genes based on HCC pathologic stage from TCGA (Kruskal-Wallis P = 1.15E-05), further solidifying an important role for LCAT in the prognosis of HCC, which was revealed through an integrated epigenomic analysis.
INtegRatIoN oF all -oMICS platFoRMS
Because epigenetic marks typically collaborate to establish functional outcomes, we simplified each of the parameters relative to important regulatory functions through ChromHMM (Fig. 4A (19) ). The data were parsed into 10 states (Fig. 2) and additional parameters (e.g., expression, 5mC, 5hmC) were linked to each state (Fig. 4A, top four panels) . States associated with promoter regions, including state 5 and state 10, have the highest level of expression and the lowest level of 5mC (Fig. 4A) . After merging the ChromHMM model, we examined differences in state calls between normal liver and HCC to identify regions where a particular state is unique to a disease stage. TCGA survival data were then linked to genes within these regions (Fig. 4B) . We observe that a greater proportion of genes associated with state 7 only in tumor are more likely to be associated with a survival difference than those where state 7 appears in both normal and tumor tissue (Fig. 4C, left) . Thus, regions that gain the active enhancer mark combination (H3K4me1 and H3K27ac) during hepatocarcinogenesis are more likely to be linked to patient prognosis, suggesting that the epigenetic change has functional consequences for the patient. A similar trend is also observed for active promoter regions (state 10; Fig. 4C, right) .
Although there are few hyper-hydroxymethylation events observed during cirrhosis and HCC progression, we nonetheless examined whether they co-localized with other marks within the genome using ChromHMM. As shown in Fig. 4D , regions marked by H3K4me1 alone (poised enhancer, state 8) or H3K4me1 and H3K27ac (active enhancer, state 7) contain the most hyper-5hmC events, whereas promoter regions including state 5 (H3K4me3 and H3K27ac) and state 10 (H3K4me3, H3K27ac, and H3K4me1) are depleted for these events, suggesting that enhancer regions are particularly important targets of aberrant epigenetic regulation by 5hmC ( Fig.  4D; Supporting Fig. S6A-C) . Because we observe enrichment of 5hmC gains in state 7, and both states 7 and 10 are enriched for genes associated with survival in HCC, we further examined these states. Expression was quantified at genes where active enhancers are gained in tumor and a significant association with patient survival was identified. Interestingly, of the 94 genes linked to a survival difference for HCC based on TCGA LIHC data, 84% are more highly expressed in the HCC samples relative to normal liver (Fig. 4E) . One such gene, COMT, displays a clear inverse correlation between 5mC and gene expression level ( Fig. 4F;  Supporting Fig. S6D, right) . Low expression of COMT is associated with poor HCC-specific prognosis (Supporting Fig. S6D, left) . Similar trends are observed for other loci including FMO3 (Supporting Fig. S6E ), whereas an inverse trend is observed for genes like Annexin A2 (ANXA2), where high expression and low methylation of ANXA2 correlate with poor survival in HCC (Supporting Fig. S6F ).
TCGA 450k data does not distinguish between 5mC and 5hmC, potentially confounding functional implications of an observed "5mC" change in disease. To address this, we examined genes showing significant increases in promoter 5hmC in our data set that overlapped with TCGA hypermethylated promoters (Supporting Fig. S7A,B) . A significant proportion of genes that sustain hyperhydroxymethylation in our data set also display elevated DNA modifications in TCGA data. Interestingly, when we examine expression from the same cohort of TCGA samples, these same loci are in general upregulated, consistent with the positive links between 5hmC and transcription (Supporting Fig. S7C ). Examination of a specific locus, the TBX15 promoter, demonstrates that this gene is hyperhydroxymethylated in HCC, with relatively modest changes in 5mC (Supporting Fig.  S7D ,E, left compared with middle panel). However, TCGA data suggest that the TBX15 promoter is hypermethylated and upregulated (Supporting Fig.  S7C-E, S7D right panel, S7E right panel) , when in fact this more likely results from elevated 5hmC that is concomitantly measured with 5mC using the Infinium 450k array.
We next integrated our epigenetic mark maps with our transcription data and coupled these to publicly available data to identify genes likely to be involved in epigenetically driving hepatocarcinogenesis. As a representative example, COMT displays DNA-based epigenetic changes at regions that lose active enhancer histone modifications in HCC relative to normal liver (Fig. 5A) . Further examination of COMT, as well as FMO3, another locus showing coordinated changes in multiple epigenetic marks and transcription, using TCGA data demonstrates that both genes are downregulated in HCC and display an inverse relationship between expression and 5mC (Supporting Fig.  S6D,E) . High levels of COMT/FMO3 expression correlate with good prognosis in patients with HCC, whereas high levels of methylation in these genes are associated with poor prognosis (Fig. 5B; Supporting  Fig. S6D,E) . Moreover, COMT and FMO3 are significantly downregulated in a panel of 50 non-tumor adjacent/HCC pairs (Fig. 5C) . Consistent with this, a majority of HCCs demonstrate promoter hypermethylation relative to their non-tumor adjacent counterparts for both COMT and FMO3 (Supporting Fig. S6I ). To determine whether these epigenetically driven silencing events (or putative epigenetic drivers of HCC) impact cell growth/survival, we ectopically expressed COMT and FMO3 in a panel of HCC-derived cell lines and measured cell viability ( Fig. 5D; Supporting Fig. S5H ) and caspase-3 activity (as a measure of apoptosis; (25) ) but has minimal impact on viability of an immortalized hepatocyte line (Hu1545). In keeping with viability, caspase-3 activity is elevated upon re-expression of COMT/FMO3 relative to the GFP control for cancer cell lines ( Fig. 5E; Supporting Fig. S5H, right) . Finally, re-expression of either FMO3 or COMT in Huh7 cells reduces their ability to invade an extracellular matrix-coated membrane (Fig. 5F) . These data therefore demonstrate that coordinated cancer-specific alterations in histone modifications, 5mC, 5hmC, and expression target genes relevant to HCC development and/or progression, and the integrated approach reveals drivers of liver cancer.
Discussion
In this study, we defined the epigenome in normal, cirrhotic, and HCC liver tissue to decipher how epigenetic marks relevant to promoter and enhancer regulation are altered individually and combinatorially during liver disease progression. We observed that histone modifications are particularly volatile, with bivalent regions being relatively unique among disease stages, and active enhancer regions showing both significant unique and shared localization among disease states. De novo acquisition of active enhancers is frequent in both cirrhosis and HCC, correlates with cancer-related pathways, and is significantly enriched for genes associated with prognosis. This is in contrast to the rest of the profiled genome where 5hmC is markedly depleted during cirrhosis and remains suppressed in HCC. Conversely, hypermethylation is abundant and displays distinct patterns between cirrhosis and HCC, where HCC is marked mainly by de novo hypermethylation events. Indeed, many CpGs undergo "switching" from 5hmC to 5mC, leading to gene repression. Integration of transcriptional and epigenetic data unveils putative epigenetically regulated drivers of HCC, including COMT and FMO3. Both of these genes, when re-expressed in HCC cell lines, significantly decrease cell viability, increase apoptosis, and decrease invasive capacity. Overall, these results demonstrate that integration of epigenetic data is a viable strategy for identifying key genes involved in hepatocarcinogenesis, potentially unveiling therapeutic targets and/or biomarkers for this notoriously hard-to-treat cancer.
Recent work has begun to implicate histone marks and their associated regulators (such as the H3K27me3 writer EZH2) in liver disease progression. High expression of EZH2 strongly correlates with poor prognosis (P = 0.004, n = 417 HCCs from TCGA). In addition, H3K4me2 (a mark linked to transcription factor binding) is depleted in HCC while the H3K4me3 writer SETD1B is overexpressed (consistent with our data; Fig. 1E ). Targeting enhancer function to treat cancer is quickly gaining traction with the BRD4 inhibitor JQ1, which interferes with enhancer activity, demonstrating antitumor activity in blood, brain, and lung cancers. (28) Interestingly, aberrant enhancer function in MLL-AF9 leukemia can be targeted therapeutically by three different mechanisms: BRD4 inhibition to broadly inhibit enhancer function, (28) disruption of a specific enhancer region by genome editing, (29) or repression of enhancer target genes, (30) highlighting the importance of enhancers in cancer and their potential as therapeutic targets. We observe that active enhancers are one of the most dramatically remodeled histone modification switching events in both cirrhosis and HCC, suggesting that genes regulated by these enhancers play important roles in the initiation (de novo enhancers in cirrhosis) and/or progression (de novo enhancers in HCC and conserved enhancer deregulation between cirrhosis and HCC) and represent an efficient way to pinpoint epigenetic driver events.
We have demonstrated here that defining the aberrant HCC epigenetic landscape using an integrated approach is a powerful tool for identifying potential driver events regulated by epigenetic mechanisms. Such events could also represent therapeutic targets. Both COMT and FMO3 were identified through analysis of histone modifications, 5mC/5hmC, transcription, and TCGA data, and were functionally assessed. COMT, which methylates catecholamines leading to their degradation, is highly expressed in normal liver, and regulates estrogen and androgen production and inactivation. COMT polymorphisms are associated with higher HCC risk in women (31) as well as for breast (32) and gastric cancers. (33) High COMT expression is associated with better prognosis in TCGA data, and it demonstrates a robust inverse correlation between expression and methylation (Supporting Fig. S6D ). Low levels of COMT promoter methylation are also associated with favorable prognosis (Fig. 5B) . Functional data support the links between methylation and expression with survival, as ectopic expression of COMT in HCC cell lines leads to reduced viability/invasion and increased apoptosis ( Fig. 5D-F) , suggesting that COMT functions as a tumor suppressor in HCC. FMO3 is the most abundant flavin-containing monooxygenase family member in liver and is responsible for degradation of xenobiotics including chemotherapeutic agents such as desatinib, imatinib, and vandetanib. (34) Furthermore, FMO3 levels are elevated in HCV-positive HCC, leading to increased carcinogenic metabolites. (35) Our data here support a role for FMO3 in HCC prognosis ( Fig. 5B; Supporting Fig. S6E ), and as a putative tumor suppressor in HCC ( Fig. 5D-F; Supporting  Fig. S6H,I ). ANXA2 is another gene derived from our data set as having a potential role in hepatocarcinogenesis (Supporting Fig. S6F ). ANXA2 is upregulated in a variety of cancers, including HCC. (36) Inhibition of ANXA2 decreases migration and invasion of HCC cells (37) and is a putative biomarker for HCC. (38) Taken together, the integrated approach used here resulted in identification of loci that have been firmly linked to hepatocarcinogenesis (e.g., ANXA2) and that represent functionally relevant epigenetically regulated genes (COMT and FMO3).
In conclusion, hepatocellular carcinoma is a notoriously hard-to-treat cancer, with few therapies available for late-stage disease. Genetic changes contributing to HCC have been thoroughly characterized, and the frequently mutated driver genes are well established (e.g., TERT, CTNNB1, TP53). (20, 39) Most of these highly mutated genes, however, are not targetable, spurring interest in alternative approaches to identify genes/ pathways critical for the initiation, progression, and metastatic potential of HCC. Epigenetic alterations remain understudied in liver cancer despite mounting evidence of their importance, including frequent mutation of epigenetic regulators ARID1A, IDH1, and BAP1. Data presented in this study identify global epigenetic defects during liver disease progression while also revealing specific loci that impact HCC biology, through integration of multiple epigenetic marks. These results therefore emphasize the importance of accounting for epigenetic changes in understanding the biology of HCC, demonstrate how epigenetic mechanisms converge to drive hepatocarcinogenesis, and serve as a model for integration of these marks to pinpoint epigenetically regulated HCC driver genes.
